# Detailed Implementation Status

Last Updated: December 11, 2025

## Executive Summary

**Repository Purpose**: Technical portfolio demonstrating expertise in oncology clinical trial programming, CDISC standards, and multi-study pipeline orchestration.

**Overall Status**: Core RECIST 1.1 derivation library complete with working demo; architecture and framework complete; comprehensive testing and validation documentation pending.

**Production Readiness**: 40-60 hours of focused development required for full production deployment.

---

## Oncology Response Library

### RECIST 1.1 Core (`etl/adam_program_library/oncology_response/recist_11_core/`)

| File | Lines | Status | Testing | Notes |
|------|-------|--------|---------|-------|
| `derive_target_lesion_response.sas` | 450 | âœ… Complete | âš ï¸ Demo only | Implements SLD calculation, 30%/20% thresholds, nadir tracking |
| `derive_non_target_lesion_response.sas` | 300 | âœ… Complete | âš ï¸ Demo only | Maps qualitative assessments to CR/NON-CR-NON-PD/PD |
| `derive_overall_timepoint_response.sas` | 500 | âœ… Complete | âš ï¸ Demo only | RECIST 1.1 Table 4 integration logic |
| `derive_best_overall_response.sas` | 280 | âœ… Complete | âš ï¸ Demo only | Confirmation logic with embedded QC |

**Module Status**: âœ… **COMPLETE**

**Testing Coverage**:
- âœ… Basic scenarios (3 subjects: CR, PR, PD)
- âš ï¸ Edge cases need expansion (see Test Scenarios section below)
- âŒ Comprehensive test suite pending

**Demo**: Working end-to-end demonstration in `demo/simple_recist_demo.sas`

---

### Time-to-Event Module (`time_to_event/`)

| File | Size | Status | Testing | Notes |
|------|------|--------|---------|-------|
| `derive_progression_free_survival.sas` | 7.8KB | âœ… Complete | âŒ Untested | Event/censor logic for PFS endpoint |
| `derive_duration_of_response.sas` | 8.2KB | âœ… Complete | âŒ Untested | DoR calculation from response to progression |
| `derive_overall_survival.sas` | 4.5KB | âœ… Complete | âŒ Untested | OS endpoint from randomization to death |

**Module Status**: âœ… Code complete | âŒ Testing pending

**Testing Requirements**:
- Need SDTM DM domain (death dates, disposition)
- Need SDTM RS domain (progression dates)
- Need test subjects with censoring scenarios

---

### Advanced Endpoints (`advanced_endpoints/`)

| File | Size | Status | Testing | Notes |
|------|------|--------|---------|-------|
| `derive_objective_response_rate.sas` | 3.9KB | âœ… Complete | âŒ Untested | ORR calculation with exact binomial CI |
| `derive_disease_control_rate.sas` | 3.7KB | âœ… Complete | âŒ Untested | DCR = CR + PR + SD |

**Module Status**: âœ… Code complete | âŒ Testing pending

**Testing Requirements**:
- Summary statistics validation
- Confidence interval accuracy checks
- Subgroup analysis testing

---

### Immunotherapy Module (`immunotherapy/`)

| File | Size | Status | Testing | Notes |
|------|------|--------|---------|-------|
| `derive_irecist_response.sas` | 9.0KB | âœ… Complete | âŒ Untested | iRECIST confirmation logic for immune-related response |
| `identify_pseudoprogression.sas` | 7.6KB | âœ… Complete | âŒ Untested | Pseudoprogression detection (initial PD â†’ response) |

**Module Status**: âœ… Code complete | âŒ Testing pending

**Testing Requirements**:
- Complex test cases with PD followed by response
- Confirmation window validation
- Edge case handling

---

## Portfolio Management & Orchestration

### Configuration Management

| Component | Status | Notes |
|-----------|--------|-------|
| `portfolio_registry.yml` | âœ… Complete | 3-study configuration with ISS/ISE pooled analyses |
| `run_all.R` | âœ… Complete | Multi-study orchestration with priority queuing |
| `automation/dependencies.R` | ðŸŸ¡ Assumed functional | Dependency tracking (not directly validated) |
| `automation/change_detection.R` | ðŸŸ¡ Assumed functional | Impact analysis for timeline changes |
| `automation/portfolio_runner.R` | ðŸŸ¡ Assumed functional | Concurrent execution engine |

**Framework Status**: âœ… Architecture complete | âš ï¸ Integration testing limited

---

### Quality Control Framework

| Component | Status | Notes |
|-----------|--------|-------|
| `qc/` directory structure | âœ… Present | QC program templates exist |
| Comparison logic (R) | âœ… Added | `qc/compare_recist_datasets.R` (diffdf-based) |
| Comparison logic (SAS) | âœ… Added | `qc/compare_recist_datasets.sas` (PROC COMPARE) |
| Reconciliation reports | âœ… Added | HTML outputs in `qc/outputs/` |
| QC manifest | ðŸŸ¡ Referenced | Exists but not validated |

**QC Status**: ðŸŸ¡ Framework designed | âœ… Comparison automation in place

**New QC Tools**:
- `qc/compare_recist_datasets.sas`: Production vs QC reconciliation with HTML summaries.
- `qc/compare_recist_datasets.R`: R-based alternative using `diffdf` for RECIST datasets.
- `qc/cl_overall_response.sas`: Investigator vs algorithm discordance listing (RS vs ADRECIST).

---

## Test Data & Validation

### Test Datasets

| Dataset | Status | Coverage | Subjects | Notes |
|---------|--------|----------|----------|-------|
| Demo SDTM RS | âœ… Created | Basic scenarios | 3 | `demo/data/test_sdtm_rs.csv` |
| Demo expected BOR | âœ… Created | Basic validation | 3 | `demo/data/expected_bor.csv` |
| Comprehensive SDTM generator | ðŸŸ¡ Template | Coverage outline | 1 | `tests/data/create_comprehensive_sdtm.sas` (needs population with 20-25 subjects) |
| Full SDTM suite | âŒ Missing | -- | 0 | Need DM, RS, TU, TR domains |
| Expected ADaM outputs | âŒ Missing | -- | 0 | Need ADSL, ADRS, ADTTE validation datasets |

**Test Data Status**: âš ï¸ Minimal demo only | âŒ Comprehensive suite needed

---

### Required Test Scenarios

#### RECIST 1.1 Core Scenarios

**Target Lesion Response**:
- [x] PR: >30% decrease from baseline (Subject 001-001)
- [x] CR: SLD = 0 (Subject 001-002)
- [x] PD: >20% + 5mm from nadir (Subject 001-003)
- [ ] SD: Neither PR nor PD criteria
- [ ] Borderline PR: Exactly 30% decrease
- [ ] Borderline PD: Exactly 20% increase but <5mm absolute
- [ ] Tie at nadir requiring evaluation
- [ ] Multiple same-day assessments

**Confirmation Logic**:
- [x] Confirmed response: 56-day interval (Subjects 001-001, 001-002)
- [ ] Confirmation window boundary: Day 28 (minimum)
- [ ] Confirmation window boundary: Day 84 (maximum)
- [ ] Unconfirmed response: Progression before confirmation
- [ ] Multiple confirmation candidates

**Non-Target Lesions**:
- [ ] All non-target absent â†’ CR
- [ ] Non-target present/stable â†’ NON-CR/NON-PD
- [ ] Non-target unequivocal progression â†’ PD
- [ ] Multiple non-target lesions (worst assessment)

**New Lesions**:
- [ ] New lesion detected â†’ automatic PD
- [ ] New lesion with target CR/PR
- [ ] Multiple new lesions at same visit

**Overall Response Table 4 Integration**:
- [x] Target=CR + NonTarget=CR â†’ Overall=CR (simplified in demo)
- [x] Target=PR + NonTarget=not assessed â†’ Overall=PR (simplified in demo)
- [ ] All 12 combinations from RECIST Table 4
- [ ] Priority hierarchy validation

**Edge Cases**:
- [ ] Missing baseline assessment
- [ ] Missing follow-up assessments
- [ ] Post-new-therapy assessment exclusion
- [ ] Multiple progressions (first takes precedence)
- [ ] Response after PD (should not override PD)

#### Time-to-Event Scenarios

- [ ] PFS: Progression date vs death date (whichever first)
- [ ] PFS: Censored at last assessment
- [ ] DoR: Response to progression interval
- [ ] DoR: Censored for ongoing responders
- [ ] OS: Death date from any cause
- [ ] OS: Censored at last contact

#### Advanced Endpoint Scenarios

- [ ] ORR: CR + PR count / total population
- [ ] ORR: Exact binomial 95% CI accuracy
- [ ] DCR: CR + PR + SD count
- [ ] DCR: Minimum SD duration requirement

---

## Validation & Compliance

### Testing Infrastructure

| Item | Status | Coverage | Notes |
|------|--------|----------|-------|
| Unit tests (testthat) | âŒ Missing | 0% | Need `tests/testthat/test-*.R` files |
| SAS macro tests | âŒ Missing | 0% | Need `%assert` or custom test framework |
| Integration tests | âŒ Missing | 0% | End-to-end pipeline validation |
| Test coverage reports | âŒ Missing | -- | Need `covr` package implementation |

**Testing Status**: âŒ No automated testing framework

---

### CDISC Compliance

| Item | Status | Notes |
|------|--------|-------|
| SDTM IG v3.4 conformance | ðŸŸ¡ Assumed | Code references standard domains/variables |
| ADaM IG v1.3 conformance | ðŸŸ¡ Assumed | BDS structure for ADRS |
| Pinnacle 21 validation | âŒ Missing | Need Community Edition reports |
| RECIST 1.1 conformance | âœ… Documented | Implementation follows Eisenhauer 2009 |

**Compliance Status**: ðŸŸ¡ Standards followed in code | âŒ Validation reports missing

---

### Regulatory Documentation

| Item | Status | Notes |
|------|--------|-------|
| Traceability matrix | âŒ Missing | Spec â†’ Code â†’ Output linkage |
| Installation Qualification (IQ) | âŒ Missing | R/SAS version documentation |
| Operational Qualification (OQ) | âŒ Missing | Package version validation |
| Performance Qualification (PQ) | âŒ Missing | Derivation accuracy on test data |
| Validation summary report | âŒ Missing | Overall validation evidence package |
| Change control log | âŒ Missing | Version history and justification |

**Validation Status**: âŒ Regulatory documentation not started

---

## Priority Action Items

### Immediate (Complete Working Demo) âœ… DONE

- [x] Implement 3 RECIST core SAS macros (8-12 hours) âœ… **COMPLETED**
- [x] Create minimal test data (3 subjects) (4-6 hours) âœ… **COMPLETED**
- [x] Create demo execution script (2-3 hours) âœ… **COMPLETED**
- [x] Document expected vs actual results (1-2 hours) âœ… **COMPLETED**
- [x] Add demo README (1-2 hours) âœ… **COMPLETED**

**Total**: 16-25 hours â†’ **COMPLETED December 11, 2025**

---

### Short-Term (Expand Test Coverage)

**Priority**: HIGH  
**Estimated Effort**: 30-40 hours

1. **Create comprehensive SDTM test suite** (12-16 hours)
   - 20-25 synthetic subjects
   - All response categories (CR, PR, SD, PD, NE)
   - Non-target lesion scenarios
   - New lesion detection cases
   - Edge cases and boundary conditions

2. **Add expected output datasets** (4-6 hours)
   - Expected ADRS for all test subjects
   - Expected ADTTE for time-to-event endpoints
   - Document derivation logic for each record

3. **Implement automated validation** (8-12 hours)
   - `PROC COMPARE` for SAS outputs
   - `diffdf` comparison for R outputs
   - Pass/fail criteria documentation

4. **Validate time-to-event macros** (6-8 hours)
   - Create test DM domain (death/disposition)
   - Test PFS/DoR/OS derivations
   - Validate censoring logic

---

### Medium-Term (Production Readiness)

**Priority**: MEDIUM  
**Estimated Effort**: 40-60 hours

1. **Implement QC automation framework** (10-15 hours)
   - Automated comparison scripts
   - HTML reconciliation report generation
   - Discrepancy investigation workflow

2. **Create unit testing suite** (15-20 hours)
   - testthat framework for R functions
   - SAS macro testing with assertions
   - 30+ test cases covering all functions
   - CI/CD integration (optional)

3. **Generate validation documentation** (15-20 hours)
   - Traceability matrix (spec â†’ code â†’ output)
   - IQ/OQ/PQ validation package
   - Test execution records
   - Validation summary report

4. **CDISC compliance validation** (5-8 hours)
   - Run Pinnacle 21 Community Edition
   - Document and resolve conformance issues
   - Generate compliance reports

5. **Create user documentation** (5-7 hours)
   - Macro parameter reference guide
   - Worked examples for each endpoint
   - Troubleshooting guide
   - Best practices documentation

---

### Long-Term (Advanced Features)

**Priority**: LOW  
**Estimated Effort**: 60-80 hours

1. **Enhanced Shiny dashboard** (20-25 hours)
   - Real-time pipeline monitoring
   - Interactive RECIST waterfall plots
   - Study comparison visualizations

2. **Advanced pooled analysis features** (15-20 hours)
   - ISS/ISE automation
   - Cross-study data harmonization
   - Meta-analysis support

3. **Performance optimization** (10-15 hours)
   - Parallel processing for large datasets
   - Memory optimization
   - Benchmarking and profiling

4. **Additional oncology endpoints** (15-20 hours)
   - RANO criteria (CNS tumors)
   - PCWG3 criteria (prostate cancer)
   - Lugano criteria (lymphoma)

---

## Contemporary Research Context (December 2024)

This repository implements RECIST 1.1 (2009) as the regulatory standard. Recent developments:

### Active Research Areas (2024-2025)

**AI-Assisted Measurement**
- Foundation models: 34.5% accuracy improvement (ASCO 2024)
- Commercial systems: RSIP Vision, Intrasense Liflow, Mint Medical
- Friends of Cancer Research ai.RECIST Project launched 2024
- **Repository Status**: Not implemented (requires DICOM integration)

**Simplified Thresholds**
- Enaworu 25mm Nadir Rule (April 2025): Single absolute threshold
- Validation: 255/255 concordance with standard RECIST 1.1 PD classification
- **Repository Status**: Not implemented (4-6 hour enhancement)

**iRECIST Validation**
- Advantage demonstrated for anti-CTLA-4 antibodies only
- No significant benefit for PD-1/PD-L1 inhibitors per 2024 meta-analysis
- Pseudoprogression biomarkers still lacking
- **Repository Status**: Code-complete but untested (20-30 hours validation needed)

**Liquid Biopsy Integration (ctDNA-RECIST)**
- Proposed framework: Collection weeks 2, 4, 8 post-treatment
- Response criteria: Non-overlapping confidence intervals
- **Repository Status**: Not implemented (requires custom SDTM domains)

### Known RECIST 1.1 Limitations (UCLA November 2024)

**Inter-Observer Variability**:
- Different target lesion selection: Îº=0.97 â†’ Îº=0.58
- Non-target "unequivocal progression": 28% of PD determinations (subjective)
- New lesion identification: 50% adjudication discordance

**Proposed Improvements** (not yet adopted):
1. Increase target lesions from 5 to 10
2. Quantify non-target with +100% doubling threshold
3. Require new lesions â‰¥10mm OR confirmatory growth

**Repository Implementation**: Uses standard RECIST 1.1 (5 lesions, qualitative non-target)

### CDISC ADRECIST v1.0 (September 2024)

**Standard Datasets**:
- ADTR: Tumor Results (lesion-level)
- ADRS: Disease Response (visit-level)
- ADINTEV: Interval Events (new lesions, deaths)
- ADEFFSUM: Efficacy Summary (BOR, confidence intervals)
- ADTTE: Time-to-Event (PFS, DoR, OS)

**Repository Alignment**:
- âœ… ADRECIST structure with horizontal CRIT variables
- âœ… Confirmation flagging (ANL01FL, ANL02FL)
- ðŸŸ¡ ADINTEV partially implemented (new lesion tracking needs expansion)
- ðŸŸ¡ ADEFFSUM partially implemented (BOR exists, CIs pending)

### Implementation Priority Matrix

| Feature | Clinical Impact | Implementation Effort | Priority |
|---------|----------------|----------------------|----------|
| Fix macro integration | Critical (consistency) | 4-6 hours | **Immediate** |
| Expand test coverage | High (validation) | 30-38 hours | **High** |
| QC automation | High (regulatory) | 15-20 hours | **High** |
| 25mm nadir rule | Medium (optional) | 4-6 hours | Medium |
| iRECIST validation | Medium (tumor-specific) | 20-30 hours | Medium |
| AI integration | Low (aspirational) | 60-80 hours | Low |
| ctDNA integration | Low (non-standard) | 40-50 hours | Low |

---

## Repository Metrics

### Code Completion

| Module | Files | Total Lines | Complete | Tested |
|--------|-------|-------------|----------|--------|
| RECIST Core | 4/4 | ~1,530 | 100% | 20% |
| Time-to-Event | 3/3 | ~600 | 100% | 0% |
| Advanced Endpoints | 2/2 | ~240 | 100% | 0% |
| Immunotherapy | 2/2 | ~510 | 100% | 0% |
| Portfolio Orchestration | 5/5 | ~800 | 100% | 50% |
| QC Framework | 4/6 | ~400 | 67% | 0% |
| **Total** | **20/23** | **~4,080** | **87%** | **15%** |

### Documentation Completion

- [x] Main README
- [x] Demo README
- [x] Implementation status (this document)
- [ ] API reference documentation
- [ ] Macro parameter guide
- [ ] Troubleshooting guide
- [ ] Validation reports
- [ ] User manual

**Documentation**: 3/8 complete (38%)

---

## Known Limitations

### Current Demo Limitations

1. **Target lesions only**: No non-target or new lesion testing
2. **Basic scenarios only**: No edge cases or boundary conditions
3. **No QC automation**: Manual comparison required
4. **No validation package**: Regulatory documentation pending
5. **Minimal test data**: Only 3 subjects, need 20-25 for comprehensive coverage

### Technical Debt

1. **No automated testing**: Unit test framework not implemented
2. **Limited error handling**: Some macros lack comprehensive input validation
3. **No logging framework**: Debug/info/error logging not standardized
4. **Hard-coded paths**: Some scripts require manual path adjustment
5. **No CI/CD pipeline**: Automated testing on commit not configured

### Scope Exclusions (By Design)

1. **Local file operations**: SAS macros are for GitHub remote operations only
2. **Real patient data**: All examples use synthetic data
3. **Production database connections**: Demo uses flat files only
4. **Electronic data capture (EDC) integration**: Out of scope
5. **Adverse event (AE) coding**: MedDRA/WHODrug integration not included

---

## Contact & Support

For questions about implementation status:

1. **Check this document** for current completion status
2. **Review GitHub Issues** for planned enhancements
3. **See demo/README.md** for quick start guide
4. **Consult main README.md** for architecture overview

---

**Document Version**: 1.0  
**Last Review**: December 11, 2025  
**Next Review**: When additional modules completed  
**Maintained By**: Christian Baghai
